Seeking Alpha
23 Jun 2026, 11:30 UTC · 13w ago
Verdict
Headline takes no side. We score ACHV +0.30 across three claims — moderately bullish.
+0.30moderately bullish
More positive than 57% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA's Complete Response Letter (CRL) is related to manufacturing and labeling rather than efficacy or safety issues.
More positive than 77% of claims this week
Achieve Life Sciences is targeting a Q4 2026 resubmission for cytisinicline.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More negative than 79% of claims this week
Cytisinicline has demonstrated very positive smoking-cessation data and potential optionality for vaping cessation.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 57% of ticker scores this week
Positive data on cytisinicline is offset by a CRL from the FDA, though the issues are limited to manufacturing and labeling.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
8h ago
+52.9%
Price agrees with the score
$7.80 vs $5.10 close before publication (Jun 22) · not market-adjusted
ACHV chart →
